Two further recent examples that showcase RNA-RBP interactions directly influencing survivability and drug sensitivity in cancer cells concern the zinc finger protein ZFP36, whose overexpression inhibited the growth of hepatocellular carcinoma (HCC) tumour cells and promoted 5-FU sensitivity in a xenograft tumour mice model [30]; and CELF2, which inhibits ovarian cancer progression and increases sensitivity to CP [31]. This evidence concerns the gene CELF2 and hepatocellular carcinoma.